The estimated Net Worth of Carl Desantis is at least $232 Milione dollars as of 12 August 2022. Carl Desantis owns over 103,952 units of iBio Inc stock worth over $1,349,000 and over the last 21 years Carl sold IBIO stock worth over $230,857,750.
Carl has made over 26 trades of the iBio Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Carl sold 103,952 units of IBIO stock worth $9,575,019 on 12 August 2022.
The largest trade Carl's ever made was selling 2,928,310 units of iBio Inc stock on 14 June 2021 worth over $183,019,375. On average, Carl trades about 176,471 units every 90 days since 2004. As of 12 August 2022 Carl still owns at least 710,000 units of iBio Inc stock.
You can see the complete history of Carl Desantis stock trades at the bottom of the page.
Carl's mailing address filed with the SEC is 109 S.E. 5TH AVENUE, SUITE 200, , DELRAY BEACH, FL, 33483.
Over the last 13 years, insiders at iBio Inc have traded over $99,626,328 worth of iBio Inc stock and bought 15,716,013 units worth $10,660,994 . The most active insiders traders include Capital Ltd Portfolio Servi..., Carl Desantis e William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of $1,893,515. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth $1,318.
ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.
iBio Inc executives and other stock owners filed with the SEC include: